Vivos Therapeutics Inc VVOS Stock Analysis

About Vivos Therapeutics Inc

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment solutions for breathing and sleep disorders arising from certain dentofacial abnormalities, including obstructive sleep apnea (OSA) and snoring in adults and children. Vivos' proprietary technologies have been cleared by the U.S. Food and Drug Administration (FDA) for use in adult patients diagnosed with all severity levels of OSA, as well as moderate-to-severe OSA in pediatric patients ages 6 to 17. The company's groundbreaking Complete Airway Repositioning and Expansion (CARE) devices represent the only FDA 510(k)-cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children. OSA affects more than one billion people worldwide, with an estimated 80% or more remaining undiagnosed. Beyond disrupted sleep, OSA is closely linked to numerous serious chronic health conditions. While legacy treatments such as CPAP have addressed symptoms, they are often mechanistic and may not address the underlying anatomical causes of the disorder. Founded in 2016 and headquartered in Littleton, Colorado, Vivos is working to transform the standard of care for sleep-disordered breathing through innovative technology, education, and strategic collaborations with sleep healthcare providers. The company's comprehensive approach-known as The Vivos Method-offers a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution, designed to address the root causes of OSA and improve long-term patient outcomes.